Journal Article

Update on the Management of Pediatric Psoriasis: An Italian Consensus

Parodi, Aurora, Hansel, Katharina, Gisondi, Paolo, Di Lernia, Vito, Micali, Giuseppe, Mazzatenta, Carlo, Restano, Lucia, Narcisi, Alessandra, Panzone, Michele, Cusano, Francesco, Fargnoli, Maria Concetta, Bonamonte, Domenico, Bernardini, Nicoletta, Fortina, Anna Belloni, Buligan, Cinzia, Simonetti, Oriana, Bongiorno, Maria Rita, Bardazzi, Federico, Gualdi, Giulio, Guarneri, Claudio, Del Giudice, Maria Beatrice De Felici, Fabbrocini, Gabriella, Neri, Iria, Peris, Ketty, Oranges, Teresa, Balato, Anna, Malara, Giovanna, El Hachem, May, Bianchi, Luca, Venturini, Marina

2022

Overview

Introduction Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis.

• Publisher: Springer Healthcare,Springer,Springer Nature B.V
• Subject: Adults / Agreements / Algorithms / Anxiety / Arthritis / Care and treatment / Child health services / Children & youth / Chronic illnesses / Coronaviruses / COVID-19 / Delphi method / Dermatologic agents / Dermatology / Diabetes / Diagnosis / Dosage and administration / Families & family life / Formulae, receipts, prescriptions / Health aspects / Internal Medicine / Medicine / Medicine & Public Health / Meetings / Oral and Maxillofacial Surgery / Original Research / Pandemics / Participation / Pediatrics / Plastic Surgery / Psoriasis / Quality of life / Quality of Life Research / Teenagers / Video teleconferencing